Host defenses against
Human infection with the eukaryotic pathogen Histoplasma capsulatum is accidental and develops when conidia and mycelial fragments become airborne from soil and are inhaled into the lungs. Transition from the mycelial to the yeast phase is a central event in pathogenesis. Once it occurs, yeasts seek intracellular residence and can be detected in several cell populations, including macrophages, dendritic cells, and neutrophils [1, 2] . Invasion of the lungs by this fungus initiates a complex inflammatory response that is regulated by cytokines and chemokines. The net result is a restriction of growth of the fungus, although tissues are not sterilized.
Perturbation of the cytokine response can lead to exacerbation of infection. Several cytokines are crucial for host defenses against H. capsulatum infection, including tumor necrosis factor (TNF)-a, interferon (IFN)-g, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin (IL)-1b [3] [4] [5] [6] [7] [8] [9] [10] . In mice, the absence of any of these cytokines converts an otherwise nonlethal infection into a lethal one. An interconnection among these cytokines during the host response is often absent. Neutralization of one does not necessarily alter the production of the others that are needed for host protection. An exception is that neutralization of GM-CSF reduces TNF-a and IFN-g levels in the lungs of infected mice [4] .
The orchestration of an appropriate inflammatory response is an important component of protective immunity to H. capsulatum infection. The IL-17 family of cytokines (in particular, IL-17A) has been shown to possess proinflammatory properties and to regulate the balance between the type 1 T helper (Th1) response and the type 2 T helper response [11] [12] [13] . Recently, IL-17 has been detected in hepatic granulomas of mice with histoplasmosis [14] .
Prompted by the above-mentioned studies, we postulated that IL-17 would be requisite for clearance of this fungus. We found that IL-17 was up-regulated in the lungs of mice during acute infection; that monoclonal antibody (MAb) to IL-17 perturbed the inflammatory response and was associated with a delayed clearance of the fungus during primary, but not secondary, infection; and that the absence of IL-17 was not associated with progressive infection. Additional experiments revealed that IL-23 could prolong the survival of mice in the absence of IL-12. This protective effect was dependent on IL-17. Thus, the IL-17/IL-23 axis promotes immunity to H. capsulatum infection. [3] . To produce primary infection, mice were intranasally inoculated with or H. capsulatum 6 6 2 ϫ 10 5 ϫ 10 yeast cells in 30 mL of Hanks' balanced salt solution (HBSS). For secondary histoplasmosis, mice were intranasally inoculated with yeast cells; 6-8 weeks later, mice were intranasally 4 1 ϫ 10 rechallenged with yeast cells. 6 2 ϫ 10 Organ culture for H. capsulatum. Recovery of H. capsulatum was performed as described elsewhere [3] . Fungal burden was expressed as the mean number (with standard errors [SEs]) of colony-forming units per organ. The limit of detection was cfu. 2 1 ϫ 10 MAb. Rat anti-mouse TNF-a (clone XT-22.1) was produced by the National Cell Culture. Rat anti-mouse IL-17A was purchased from R&D Systems.
METHODS

Mice
Treatment with MAb. Mice were intraperitoneally injected with MAb on the day of infection and each week thereafter; 1 and 200 mg of MAb to TNF-a and IL-17A were administered, respectively. Control mice received rat IgG.
Preparation of lung leukocytes. Lungs were dissociated in 5 mL of HBSS by means of a gentleMACS Dissociator instrument (Miltenyi Biotec) and treated for 30 min with 1 mg/mL collagenase plus 30 mg/mL DNase at 37ЊC. The solution was filtered through 60-mm nylon mesh and washed 3 times with HBSS. Leukocytes (197% CD45 + ) were isolated by gradient density centrifugation using Lympholyte-M medium (Cedarlane Laboratories).
Flow cytometry. The following MAbs were purchased from BD Biosciences: fluorescein isothiocyanate-conjugated CD11c, CD69, CD8a, and I-A b ; phycoerythrin-conjugated Mac-3 and Ly6G; allophycocyanin-conjugated CD11c, CD3e, CD62L, and CD25; and peridin-chlorophyll protein-conjugated CD4 and CD11b. Two million cells were incubated with 0.5 mg of MAb in staining buffer (1% bovine serum albumin in phosphate buffered saline) for 10 min at 4ЊC. Cells were washed in staining buffer, and fluorescence was measured using a FACScaliber flow cytometer (BD Biosciences). Between 50,000 and 100,000 events were counted.
Intracytoplasmic staining. Cells were stained with MAb to CD69, CD4, CD8a, and CD25, followed by permeabilization of cells and staining with phycoerythrin-conjugated anti-IL-17A (BD Pharmingen) as described elsewhere [15] .
RNA isolation and cDNA synthesis. RNA was isolated from mouse lungs by means of TRIzol reagent (Invitrogen) and cDNA synthesized as described elsewhere [5] .
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR). qRT-PCR for IL-17A, IL-17F, and IL-23 was performed using TaqMan primers (Applied Biosystems). Samples were analyzed on an ABI Prism 7500 instrument (Applied Biosystems). Transcript quantities were standardized to expression in an uninfected lung. In each experiment, the hypoxanthine phosphoribosyl transferase gene was analyzed, and data were expressed as the log 10 of relative quantification. The conditions for amplification were: 50ЊC for 2 min, 95ЊC for 10 min, and 40 cycles of 95ЊC for 15 s and 60ЊC for 1 min.
Cytokine analysis of lung homogenates. Lung homogenates were prepared as described elsewhere [3] , and levels of IL-4, IL-6, IL-10, IFN-g, IL-17, IL-23, GM-CSF, and TNF-a were quantified by enzyme-linked immunosorbent assay (ELISA; R&D Systems).
Statistical analysis. Analysis of variance (ANOVA) was used to compare groups. The log rank sum test was used to analyze survival. Differences with were considered sta-P ! .05 tistically significant.
RESULTS
IL-17 in murine histoplasmosis.
The generation of IL-17 in the lungs of mice infected with H. capsulatum yeast 6 2 ϫ 10 cells was examined. Expression of IL-17A and IL-17F was detectable by qRT-PCR on day 3, peaked on day 7, and declined abruptly thereafter ( figure 1A ). IL-17 protein in lung homogenates was assessed by ELISA; peak production occurred on day 7 and declined rapidly afterward ( figure 1B) .
Profile of IL-17 + cells in the lungs of mice with pulmonary histoplasmosis. Among lung leukocytes, 4.1% ‫ע‬ 0.7% were 
Blunting of immunity by treatment with MAb to IL-17A.
Infected mice were treated with anti-IL-17A or control antibody, and fungal burden was assessed on day 7. Neutralization of IL-17A blunted clearance ( figure 2A ). Because anti-IL-17A diminished the capacity to clear infection at its peak, we asked whether continued neutralization would affect survival. Ninety percent of mice given anti-IL-17A survived for up to 40 days ( figure 2B ). This finding prompted us to examine the fungal burden over time. Mice were infected and given MAb to IL-17A, and fungal burden was determined at intervals. The number of H. capsulatum in the lungs and spleens was similar between infected control mice and anti-IL-17A recipients on day 4. By day 7, the burden was higher in the lungs of mice whose IL-17A was neutralized and remained elevated relative to that in control mice on days 14, 21, and 30 (figure 2C and 2D). In this set of experiments, 1 mouse died on day 13. Surviving mice given MAb to IL-17A manifested a decrement in fungal burden over time. Despite the increase in colony-forming unit counts on day 7, the mice were able to contain the infection.
To determine whether these results were a consequence of inoculum size, mice were challenged with a higher but nonlethal inoculum ( yeast cells) and given control antibody or 6 5 ϫ 10 MAb to IL-17A. On day 7, neutralization of IL-17A caused a modest but statistically significant increase in colony-forming unit counts ( , ANOVA) ( figure 2E ). There were no sta-P ! .05 tistically significant differences in survival ( , log rank P у .05 sum test) ( figure 2F ).
An elevation in colony-forming unit counts of the magnitude that we observed in IL-17A-neutralized mice is predictive of a lethal outcome. This supposition stems from observations made 2 ϫ 10 Mice were killed on day 7, and mean colony-forming unit counts were determined in lungs (A) and spleens (B) from 6-8 mice per group; bars represent standard errors. Panel C shows survival curves for mice administered MAb to IL-17A, TNF-a, or TNF-a plus IL-17A (6-10 mice per group). **P ! (analysis of variance). .01 in mice given MAb to TNF-a, GM-CSF, or IFN-g [3, 4, 16] . Therefore, we repeated the experiments using MAb to TNF-a and MAb to IL-17A. We also asked whether neutralization of IL-17A altered the response in mice given MAb to TNF-a. Treatment with MAb to IL-17A or to TNF-a induced a similar increase in colony-forming unit counts on day 7 (figure 3A and 3B); treatment with both caused a slight increase above that of each alone. Neutralization of TNF-a or of TNF-a plus IL-17A was lethal ( figure 3C ).
To determine whether IL-17 altered the host response in secondary histoplasmosis, previously infected mice were rechallenged with yeast cells, and fungal burden and sur- 6 2 ϫ 10 vival were assessed. On day 7 of infection, the log 10 colonyforming unit counts in the lungs (mean ‫ע‬
Inflammatory response in the lungs of mice given MAb to IL-17A. On day 7 of infection, we analyzed the inflammatory response in the lungs of mice given anti-IL-17A or control antibody. We chose this day because it represented the peak in the disparity in fungal burden. Proportionally, the CD8 + cell population in recipients of MAb to IL-17A was statistically significantly reduced, compared with that in control mice ( , ANOVA) ( figure 4A ). Mice given MAb to IL-17A ex-P ! .05 hibited a markedly decreased number of total leukocytes in the lungs ( , ANOVA). Consequently, the number of each of P ! .01 the inflammatory cell populations examined was statistically significantly depressed ( , ANOVA with Bonferroni's cor-P ! .01 rection) (figure 4B).
Cytokine response in the lungs. We examined the generation of TNF-a, IFN-g, GM-CSF, IL-4, IL-6, and IL-10 in the lungs of infected control mice and recipients of anti-IL-17A. There were no marked disturbances in GM-CSF, IFN-g, or TNF-a production. However, statistically significant increases in IL-10 and IL-6 levels in mice receiving MAb to IL-17A were apparent (table 1) .
To determine whether the increase in the IL-10 level was biologically relevant, IL-10 Ϫ/Ϫ mice were given rat IgG or MAb to IL-17A and infected with H. capsulatum. Neutralization of IL-17A did not alter the fungal burden on day 7 of infection in IL-10 Ϫ/Ϫ mice, although it did affect wild-type (WT) mice.
The log 10 colony-forming unit counts in the lungs ( -7) n p 6 of WT mice given rat IgG (mean ‫ע‬ SE, ) were sta-6.3 ‫ע‬ 0.3 tistically significantly lower than those in the lungs of WT mice given MAb to IL-17A (mean ‫ע‬ SE, ) ( , 7.5 ‫ע‬ 0.5 P ! .01 ANOVA). In contrast, the fungal burden in the lungs of IL-10 Ϫ/Ϫ mice administered rat IgG (mean ‫ע‬ SE, ) did 6.4 ‫ע‬ 0.2 not differ from that of IL-10 Ϫ/Ϫ mice administered MAb to IL-17A (mean ‫ע‬ SE, ) ( , ANOVA). No differences 6.7 ‫ע‬ 0.5 P у .05 were observed for spleens between the groups (data not shown).
IL-6 and IL-17. The generation of IL-17 by T cells is reported to be partially dependent on the presence of IL-6, although an alternate pathway of induction exists [17, 18] . Surprisingly, the proportion and number of cells in IL-6 Ϫ/Ϫ mice that generated IL-17 was not much different than those in WT mice ( figure 1C-1F) . Because IL-6 levels were elevated in mice given anti-IL-17A, we ascertained whether IL-17 affected host resistance in IL-6 Ϫ/Ϫ mice. MAb to IL-17A failed to exacerbate infection in IL-6 Ϫ/Ϫ mice. Log 10 colony-forming unit counts in IL-6 Ϫ/Ϫ mice given control antibody (mean ‫ע‬ SE, 7.0 ‫ע‬ 0.4;
) were similar to those in mice given MAb to IL-17A n p 8 (mean ‫ע‬ SE, ). No difference was observed for spleens 7.2 ‫ע‬ 0.6 (data not shown). bicans and Aspergillus fumigatus [19] . We initially asked whether IL-23 was produced during infection. In the lungs of infected mice, IL-23 levels peaked on day 7 of infection and decreased thereafter, as assessed by qRT-PCR (figure 5A). As assessed by ELISA, IL-23 levels were undetectable on day 1 but gradually increased on days 3-7 (figure 5B).
IL-17/IL-23 axis. The IL-17/IL-23 network is important in the control of several infectious agents, including Candida al-
Administration of neutralizing MAb to the p40 subunit of IL-12 impairs protective immunity to H. capsulatum infection [9, 20] . This finding was interpreted to signify the importance of IL-12 in host defenses. However, these studies were conducted before the discovery of IL-23, and it is now apparent that neutralizing the activity of p40 impairs both IL-12 and IL-23. Therefore, we examined whether IL-23 was important to the host defense. IL-12p35 Ϫ/Ϫ mice (lacking IL-12) and IL12p40 Ϫ/Ϫ mice (lacking IL-12 and IL-23) were intranasally inoculated with H. capsulatum, and fungal burden on day 7 of infection and survival were analyzed. Both groups had elevated colony-forming unit counts in lungs and spleens on day 7 of infection ( figure 5C and 5D ), but p35 Ϫ/Ϫ mice exhibited prolonged survival, compared with p40 Ϫ/Ϫ mice ( , log rank P ! .01 sum test) (figure 5E). To examine whether IL-17 was involved in the prolonged survival of mice that could generate IL-23, infected p35 Ϫ/Ϫ mice were treated with MAb to IL-17A. Survival was statistically significantly truncated in mice given MAb to IL-17A ( , log rank sum test) ( figure 5F ). P ! .01
DISCUSSION
Here, we have demonstrated that IL-17 is necessary for generation of an optimal inflammatory and protective immune response in murine pulmonary histoplasmosis. However, neutralization of 17A did not abolish immunity in the intact host, suggesting that it may be dispensable for protective immunity. In contrast, IL-17 was requisite for the protective effect induced by IL-23 in the absence of IL-12. The inability to profoundly impact host resistance was independent of inoculum size. Mice given anti-IL-17A and a greater number of yeast cells manifested an elevated fungal burden but not higher mortality. We did not assess lethal inocula in these experiments because neutralization was shown only to exacerbate, rather than ameliorate, fungal burden. The detrimental effect of anti-IL-17A was accompanied by increases in IL-10 and IL-6 and a sharp decrease (∼70%) in the number of leukocytes in the lungs. Despite alterations, the overwhelming majority of mice survived.
IL-17 constitutes a cytokine family that includes A, B, C, D (IL-27), E (IL-25), and F. As assessed by qRT-PCR, the temporal expression of IL-17A and IL-17F in infected lungs was similar, with a peak on day 7. IL-17A and IL-17F can exist as A or F homodimers or as A-F heterodimers [21] . The majority of biological activity resides with the A homodimers or A-F heterodimers; both the A homodimers and the A-F heterodimers are inactivated by MAb to IL-17A [21] . An explanation for the finding that mice did not die of infection is that IL-17A and IL-17F cooperate to confer protection against H. capsulatum. If both cytokines were antagonized, the effect may have been more pronounced. This assertion is unlikely, given that the effect of anti-IL-17A on day 7 of infection was as striking as that induced by MAb to TNF-a, yet mice given the latter did not recover. Moreover, anti-IL-17A would attenuate the action of IL-17A and A-F heterodimers [21] . The role played by IL-17F in histoplasmosis requires additional investigation.
IL-17 influences protective immunity to numerous pathogens, including bacteria, fungi, and protozoa [19, [22] [23] [24] [25] [26] [27] [28] . Our model contrasts with many infectious models in which the absence of IL-17 induces a profound loss in immunity. The influence of IL-17A neutralization on fungal burden was not observed earlier than day 7, when cellular immunity is engaged [29] . On day 4, colony-forming unit counts were similar between mice given MAb to IL-17A and control mice. However, these data do not exclude the possibility that neutralization of IL-17A affects inflammatory cell recruitment before day 7. The findings indicate that innate immunity does not rely on IL-17 to control H. capsulatum infection, whereas cellular immunity does. In contradistinction, neutralization of IL-17A did not thwart the efficacy of protective immunity in secondary infection. The absence of IL-17 is dispensable when Th1 immunity preexists. These results contrast with the requirement for IL-17 in vaccine-induced immunity to Mycobacterium tuberculosis and Bordetella pertussis infection [30, 31] .
As a molecular effector, IL-17 possesses a number of functions. Recognized for its ability to mobilize neutrophils, this cytokine also enhances the development of osteoclasts, the expression of b-defensins, and the antifungal activity of neutrophils [12, 32, 33] . It is a central component of pathologic inflammation manifest in experimental autoimmune encephalomyelitis, rheumatoid arthritis, and inflammatory bowel disease [17, [34] [35] [36] . Neutralization of IL-17A in mice Neutralization of IL-17A did not induce a dramatic alteration in the cytokine profile in the lungs of infected mice. The only major disturbance was an increase in the IL-10 level, which is known to impair protective immunity to H. capsulatum [44] . The levels of IFN-g, TNF-a, and GM-CSF, all effectors that are necessary for protective immunity, were not different from those in control mice. This finding contrasts with that found using models of C. albicans and A. fumigatus infection, in which IL-17A negatively regulates Th1 responses [19, 45, 46] . The elevation in the IL-10 level was functionally important, given that neutralization of IL-17A in IL-10 Ϫ/Ϫ mice failed to increase fungal burden. Although IL-10 is known to depress IL-17 levels, scant literature on the influence of IL-17 on IL-10 exists [47] . The paucity of data intimates that these 2 cytokines may counterregulate one another. IL-17 interacts with TNF-a to regulate the generation of cytokines or chemokines [48] . We endeavored to determine whether IL-17 altered the host response in H. capsulatuminfected mice given MAb to TNF-a. We hypothesized that neutralization of IL-17A might mitigate the severity of infection found in mice lacking TNF-a. However, the converse occurred, albeit slightly. Thus, TNF-a and IL-17 are not antagonistic but rather work in concert in host defenses.
Previous studies had shown that neutralization with a MAb to the p40 protein in mice produces progressive histoplasmosis [9, 20] . The original interpretation was that IL-12 was essential, but this was asserted before the discovery of IL-23, which shares p40 with IL-12 and contains a unique p19 protein [49] . We revisited our earlier results to determine whether IL-23 contributed to the protective immune response to H. capsulatum. Although mice lacking p40 or p35 died, the survival time in mice lacking p35 was extended, compared with that in mice lacking p40. This finding demonstrates that IL-23 can promote immunity in mice. Another key finding was that prolonged survival in IL-23-producing mice was critically dependent on IL-17A. These results unequivocally indicate that the IL-17/IL-23 axis influences the host response to H. capsulatum. The results extend previous findings regarding the significance of the IL-17/IL-23 pathway to another fungal pathogen, C. albicans [19] .
In summary, IL-17 and IL-23 influence the protective response to this fungus. IL-17 regulates the inflammatory response and optimizes host control of infection. IL-17 contributes to immunity only when IL-10 and IL-6 are present. Although a lack of IL-17 did not lead to unrestrained infection, it is possible that deficiencies in IL-17 and other cytokines (such as TNF-a) may tip the balance of immunity in favor of the fungus. Our findings emphasize the complexity of the host response to this eukaryotic pathogen and provide insights into the molecular effectors that confer an effective immune response.
